VistaGen Therapeutics (NASDAQ:VTGN) Upgraded at Wall Street Zen

VistaGen Therapeutics (NASDAQ:VTGN) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other analysts have also recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, January 21st. Stifel Nicolaus downgraded VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price objective on the stock. in a report on Wednesday, December 17th. Maxim Group reaffirmed a “hold” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Jefferies Financial Group reiterated a “hold” rating and issued a $0.90 target price (down from $15.00) on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Finally, William Blair restated a “market perform” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, VistaGen Therapeutics currently has an average rating of “Reduce” and an average price target of $0.95.

VistaGen Therapeutics Trading Down 7.2%

Shares of NASDAQ VTGN opened at $0.51 on Friday. The company has a market cap of $19.97 million, a price-to-earnings ratio of -0.27 and a beta of 0.32. VistaGen Therapeutics has a 12 month low of $0.43 and a 12 month high of $5.14. The stock has a 50-day moving average price of $1.17 and a two-hundred day moving average price of $2.81.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings results on Thursday, February 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.06. The company had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.14 million. On average, sell-side analysts predict that VistaGen Therapeutics will post -1.77 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Two Sigma Investments LP boosted its stake in shares of VistaGen Therapeutics by 223.5% in the 3rd quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock valued at $1,027,000 after purchasing an additional 199,958 shares during the last quarter. Jane Street Group LLC acquired a new position in VistaGen Therapeutics in the second quarter valued at $190,000. Dimensional Fund Advisors LP boosted its position in VistaGen Therapeutics by 123.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 151,874 shares of the company’s stock valued at $101,000 after acquiring an additional 83,857 shares during the last quarter. Geode Capital Management LLC grew its holdings in VistaGen Therapeutics by 18.3% during the 4th quarter. Geode Capital Management LLC now owns 352,836 shares of the company’s stock worth $234,000 after acquiring an additional 54,556 shares during the period. Finally, Stempoint Capital LP grew its holdings in VistaGen Therapeutics by 2.0% during the 2nd quarter. Stempoint Capital LP now owns 2,413,254 shares of the company’s stock worth $4,827,000 after acquiring an additional 46,700 shares during the period. Institutional investors and hedge funds own 78.39% of the company’s stock.

Trending Headlines about VistaGen Therapeutics

Here are the key news stories impacting VistaGen Therapeutics this week:

• Positive Sentiment: Q3 results beat consensus on both EPS and revenue (reported loss $0.45/sh vs. est. $0.51; revenue $0.30M vs. est. $0.14M), which is supportive for the stock as it shows slightly better-than-expected financial performance. Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results
• Neutral Sentiment: Management provided a corporate update saying it reviewed PALISADE-3 data and implemented “moderate refinements,” language that is ambiguous for program outlook until full details from the company/meeting are disclosed; investors will look to the earnings call/transcript for color. Earnings Press Release / Call Materials Q3 2026 Earnings Call Transcript
• Negative Sentiment: A large cluster of investor alerts and class-action solicitations from multiple law firms (Robbins LLP, Schall Law Firm, Rosen, Pomerantz, DJS, Bernstein Liebhard, Gross, etc.) allege Vistagen misled investors about trial viability and seek lead plaintiffs — this increases legal overhang, raises potential litigation costs, and is the most likely proximate cause of downward pressure on the stock. Representative notices: Robbins LLP Notice Schall Law Firm Notice DJS Law Group Notice

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.